Cytochrome P450 1 enzyme inhibition and anticancer potential of chromene amides from amyris plumieri

Fitoterapia

Volumn 82, Issue 2, 2011, Pages 230-236

  Badal, S ^a   Williams, S A ^a   Huang, G ^b   Francis, S ^a   Vendantam, P ^b   Dunbar, O ^a   Jacobs, H ^a   Tzeng, T J ^b   Gangemi, J ^b   Delgoda, R ^a  

^a UNIVERSITY OF THE WEST INDIES   (Jamaica)

^b CLEMSON UNIVERSITY   (United States)

Author keywords

Anticancer; Chemoprevention; Chemoprotection; CYP450; Jamaica; Natural products

Indexed keywords

ANTINEOPLASTIC AGENT; CHROMENE DERIVATIVE; CYTOCHROME P450; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 1B1; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; ENZYME INHIBITOR; TYRAMINE;

AMYRIS PLUMIERI; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELL STRAIN MCF 7; CHEMOPROPHYLAXIS; CYTOTOXICITY; DRUG ISOLATION; DRUG STRUCTURE; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; MEDICINAL PLANT; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

AMYRIS;

EID: 79952361428     PISSN: 0367326X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fitote.2010.10.003     Document Type: Article

References (30)

1. Fuente GDL, Reina M, Timon I. Chromene amides from Amyris texana. Phytochemistry 1991;30:2677-84.
2. Hartwell J. Plants used against cancer: a survey. Lloydia 1968;31(2): 171-9.
3. Giddens A, Boshoff H, Franzblaus B, Copp B. Antimycobacterial natural products; synthesis and preliminary biological evaluation of the oxazole containing alkaloid texaline. Tetrahedron Lett 2005;46:7355-7. (Pubitemid 41365850)
4. Shimada T. Xenobiotic metabolizing enzymes involved in activation and detoxification of carcinogenic polycyclic aromatic hydrocarbons. Drug Metab Pharmacokinet 2006;21:257-76.
5. Levin W, Wood A, Yari H, Jerina DM, Conney AH. (±)-Trans-7, 8-dihydroxy-7, 8-dihydrobenzo[a]pyrene: a potent skin carcinogen when applied topically to mice. Proc Natl Acad Sci USA 1976;73: 3867-71.
6. Shimada T, Fujii-Kuriyama Y. Metabolic activation of polycyclic aromatic hydrocarbons to carcinogens by cytochrome P50 1A1 and 1B1. Cancer Sci 2004;95:1-6. (Pubitemid 38208399)
7. Shimada T, Oda Y, Gillam EMJ, Guengerich FP, Inoue K. Metabolic activation of polycyclic aromatic hydrocarbons and their dihydridiol derivation and other procarcinogens by cytochrome P450 1A1 and 1B1 allelic variants and other human cytochrome P450 enzymes in Salmonella typhimurium NM2009. Drug Metab Dispos 2001;29: 1179-82.
8. Zhang KL, Ma JX, Chen XY, Sun Y, Kong QY, Liu J, et al. Frequent CYP1A1 expression in gastric cancers and their related lesions. Oncol Rep 2004;12:1335-40.
9. Buters JT, Sakai S,Richter T, Pineau T, AlexanderDL, SavasU, et al.Cytochrome P450 CYP1B1 determines susceptibility to 7, 12-dimethylbenz[a] anthraceneinduced lymphomas. Pro Natl Acad Sci USA 1999;96:1977-82. (Pubitemid 29117853)
10. Skupinska K, Misiewicz-Krzeminska I, Stypulkowski R, Lubelska K, Kasprzycka-Guttman T. Sulforaphane and its analogues inhibit CYP1A1 and CYP1A2 activity induced by benzo[a]pyrene. J Biochem Mol Toxicol 2009;23(1):18-28.
11. Hecht S, Kenny P, Wang M, Upadhyaya P. Benzyl isothiocyanate: an effective inhibitor of polycyclic aromatic hydrocarbon tumorigenesis in A/J mouse lung. Cancer Lett 2002;187:87-94. (Pubitemid 35279336)
12. Yuan P, Chen BA, Liu DL. Anticancer mechanisms and researches of isothiocyanates. Chin J Nat Med 2008;6:325-32.
13. Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res 2003;23:363-98. (Pubitemid 36361976)
14. Thapliyal R, Maru GB. Inhibition of cytochrome P450 isozymes by curcumins in vitro and in vivo. Food Chem Toxicol 2003;39:541-7.
15. Crespi CL, Miller VP, Penman BW. Microtitre plate assays for inhibition of human, drug metabolising cytochromes P450. Anal Biochem 1997;248:188-90. (Pubitemid 27218241)
16. Palmari J, Dussert C, Berthois Y, Penel C, Martin PM. Distribution of estrogen receptor heterogeneity in growing MCF-7 cells measured by quantitative microscopy. Cytometry 1996;27:26-35. (Pubitemid 27059779)
17. Heusch WL, Maneckjee R. Effects of bombesin on methadone-induced apoptosis of human lung cancer cells. Cancer Lett 1999;136:177-85. (Pubitemid 29164393)
18. Powrie RH. High-throughput inhibition screening of five major human cytochrome P450 enzymes using an in-vitor substrate cocktail. CXR biosciences. Available at http://www.cxrbiosciences.com/cmsimages/ media/pdfs/ Microsoft%20PowerPoint%20-%20P450%20inhibition% 20poster.pdf Accessed on April 20,2010.
19. Stresser DM, Broudy MI, Ho T, Cargill CE, Blnachard AP, Sharma R, et al. Highly selective inhibition of human CYP3A in vitro by azmulin and evidence that inhibition is irreversible. Drug Metab Dispos 2004;32: 105-12. (Pubitemid 38112542)
20. Cali J. Screen for CYP450 inhibitors using P450-GLOTM luminescent cytochrome P450 assays. cell notes issue available at www.promega. com 2003.
21. McLaughlin LA, Dickman LJ, Wolf CR, Henderson CJ. Functional expression and comparative characterisation of nine murine cytochromes P450 by fluorescent inhibition screening. Drug Metab Dispos 2008;36:1322-31. (Pubitemid 351929317)
22. Gerhäuser C, Klimo K, Heiss E, Neumann I, Gamal-Eldeen A, Knauft J, et al. Mechanism-based in vitro screening of potential cancer chemopreventive agents. Mutat Res 2003;523-524:163-72. (Pubitemid 36293243)
23. Gusman J, Malonne H, Atassi G. A reappraisal of the potential chemopreventive and chemotherapeutic properties of resveratrol. Carcinogenesis 2001;22:1111-7. (Pubitemid 32737324)
24. Forti R, Wahlstrom J. CYP2C19 inhibition: The impact of substrate probe selection on in vitro inhibition profiles. Drug Metab Dispos 2008;36(3): 523-8. (Pubitemid 351397977)
25. Ware WR. Nutrition and the prevention and treatment of cancer: association of cytochrome P450 CYP1B1 with the role of fruit and fruit extracts. Integr Cancer Ther 2009;8:22-8.
26. Martinez V, O' Connor R, Liang Y, Clynes M. CYP1B1 expression is induced by docetaxel: effect on cell viability and drug resistance. Br J Cancer 2008;98:564-70. (Pubitemid 351214524)
27. Castro DJ, Baird WM, Pereira CB, Giovanni J, Löhr C, Fischer K, et al. Fetal mouse cyp1b1 and transplacental carcinogenesis from maternal exposure to dibenzo[a, l]pyrene. Cancer Prev Res 2008;1:128-34.
28. Shields M, Niazi U, Badal S, Yee T, Sutcliffe M, Delgoda R. Inhibition of CYP1A1 by Quassinoids found in Picrasma excelsa. Planta Med 2009;75: 137-41.
29. Badal S, Shields M, Niazi U, Jacobs H, Sutcliffe M, Delgoda R. Screening natural products for CYP1 inhibitors. Proceedings of the 17th International Symposium on Microsomes and Drug Oxidation. Saratoga Springs, New York, U.S.A. Medimond Publishers; 2008. p. 20-4.
30. Ciolino H, Yeh G. The flavonoid galangin is an inhibitor of CYP1A1 activity and an agonist/antagonist of the aryl hydrocarbon receptor. Br J Cancer 1999;79(9/10):1340-6. (Pubitemid 29116788)